CBTF Programs and Research

Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

A cohort study identified factors associated with late deaths in childhood cancer survivors.

In this episode of "The Vitals," Ellen Miller, MSN, FNP-BC, talks about meeting a patient who realized she wanted to get pregnant after undergoing chemoradiation as a teenager.

Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.

According to Fennec Pharmaceuticals, the National Comprehensive Cancer Network is updating it guidelines to recommend injections of sodium thiosulfate to reduce the risk of ototoxicity in pediatric patients receiving cisplatin.